Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 206,700 shares, a growth of 8.1% from the September 30th total of 191,300 shares. Approximately 3.5% of the shares of the company are short sold. Based on an average daily volume of 4,750,000 shares, the short-interest ratio is presently 0.0 days.

Avalon GloboCare Stock Performance

Avalon GloboCare stock opened at $3.33 on Thursday. Avalon GloboCare has a 1 year low of $2.42 and a 1 year high of $21.60. The firm’s 50-day moving average is $3.56 and its 200-day moving average is $4.99. The company has a market cap of $36.98 million, a P/E ratio of -2.36 and a beta of 0.31.

Avalon GloboCare (NASDAQ:ALBT) last issued its earnings results on Monday, August 19th. The company reported ($2.85) earnings per share (EPS) for the quarter. The business had revenue of $0.33 million for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.